ST. LOUIS, Feb. 20, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data presentations at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of ASBMT and CIBMTR, Feb. 20 – 24 in Houston. New data will be presented on WUGEN's core platform technology supporting its "off-the-shelf," fratricide-resistant CAR-T cell therapy for T-cell malignancies.
"We are driving innovation in CAR-T therapies with our novel technology platform," said John McKearn, Ph.D., CEO of WUGEN. "Our preclinical data validate the use of allogeneic 'off-the-shelf' adoptive immunotherapy for the treatment of Sézary syndrome, bringing hope to an underserved patient population. These findings will allow us to advance our understanding of CAR-T therapies to improve patient outcomes."
Presentations:
Title: A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing (Abstract #223) Presented: Matt L. Cooper, Ph.D., Washington University of St. Louis Date/Time: Wednesday, Feb. 20 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3
Title: Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy (Abstract #228) Presented: Karl W. Staser, Ph.D., Washington University of St. Louis Date/Time: Wednesday, Feb. 20 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3
Title: CS1 Targeted Chimeric Antigen Receptors (CAR) for Treatment of Multiple Myeloma (Abstract #579) Presented: Julie O'Neal, Ph.D., Washington University of St. Louis Date/Time: Saturday, Feb. 23 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3
About WUGEN
WUGEN Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis. For more information please visit www.wugen.com.
For media inquiries contact: David Schull or Travis KruseRusso Partners858-717-2310212-845-4272david.schull@russopartnersllc.com [email protected]
Advertisement
"We are driving innovation in CAR-T therapies with our novel technology platform," said John McKearn, Ph.D., CEO of WUGEN. "Our preclinical data validate the use of allogeneic 'off-the-shelf' adoptive immunotherapy for the treatment of Sézary syndrome, bringing hope to an underserved patient population. These findings will allow us to advance our understanding of CAR-T therapies to improve patient outcomes."
Advertisement
Presentations:
Title: A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing (Abstract #223) Presented: Matt L. Cooper, Ph.D., Washington University of St. Louis Date/Time: Wednesday, Feb. 20 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3
Title: Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy (Abstract #228) Presented: Karl W. Staser, Ph.D., Washington University of St. Louis Date/Time: Wednesday, Feb. 20 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3
Title: CS1 Targeted Chimeric Antigen Receptors (CAR) for Treatment of Multiple Myeloma (Abstract #579) Presented: Julie O'Neal, Ph.D., Washington University of St. Louis Date/Time: Saturday, Feb. 23 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3
About WUGEN
WUGEN Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis. For more information please visit www.wugen.com.
For media inquiries contact: David Schull or Travis KruseRusso Partners858-717-2310212-845-4272david.schull@russopartnersllc.com [email protected]
View original content:http://www.prnewswire.com/news-releases/wugen-presents-new-data-for-key-car-t-platform-at-the-2019-transplantation--cellular-therapy-meetings-of-asbmt-and-cibmtr-300799182.html
SOURCE WUGEN Inc.
